Bupropion's Bioinequivalence

Total Page:16

File Type:pdf, Size:1020Kb

Bupropion's Bioinequivalence Bupropion’s Bioinequivalence: Patient Variability, Absorption, and Metabolism by Jamie Nicole Connarn A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Pharmaceutical Sciences) in the University of Michigan 2015 Doctoral Committee: Professor Duxin Sun, Chair Professor Gordon L. Amidon Professor Vicki L. Ellingrod Professor David E. Smith ©Jamie N. Connarn 2015 Dedication To my family for all their love, prayers, and support; especially my Mom. ii Acknowledgements First and foremost, I would like to thank my advisor, Dr. Duxin Sun for all the remarkable opportunities that he gave me during my graduate career as well as the full support and training. Without all his support, knowledge, and dedication to producing successful graduate students, this would not be possible. I would like to thank my committee members; Dr. David Smith, Dr. Gordon Amidon, and Dr. Vicki Ellingrod for all their insightful expertise in guiding my research smoothly. I would also like to thank Dr. Jason Gestwicki, who was a huge help on my Heat Shock Protein studies. In addition, I would like to thank Dr. Rose Feng, Dr. Simon Zhou, and Dr. Yan Li for collaborative projects and all the assistances with my PK analysis. I am grateful for all my lab mates and staff; Hayley Paholak, Joe Burnett, Becky Reed, Xiaoqing Ren, Kanokwan Sansanaphongpricha, Albert Lin, Mari Gasparyan, Alex Yu, Ila Myers, Nathan Truchan, Huixia Luo, Dr. Hongwei Chen, Dr. Ruijuan Luo, Dr. Ting Zhao, Dr. Bo Wen, Dr. Siwei Li, Dr. Xiaoqin Li, Dr. Yasuhiro Tsume, Marisa Gies, and Gail Benninghoff. In addition, I would like to thank those who were a part of our large clinical team; Marisa Kelly, Gloria Harrington, Stephanie Flowers, Kirsten Weiss, Xinyuan (Susie) Zhang, and Andrew Babiskin I would like to express how grateful I am for all of my friends I have met here; Xiaomei Chen, Amy Doty, Morgan Giles, Kelly Hansen, Eric Lachacz, Maya Lipert, Max Mazzara, Allison Maytas, Max Stefan, Charlie Steffens, Arjang Talattof, Karthik Pisupati, Maria Posada, and too many more. I will always remember our great times iii together in Ann Arbor. A special thanks to two of my best friends who helped me through many times over years; Melissa Benham and Maryann Oram. Finally, I would like to thank all of my family especially; my parents Leslie Persin and Jim Connarn and my sister Jennifer and Jessica Connarn for their love and support. iv TABLE OF CONTENTS Dedication ........................................................................................................................ii Acknowledgements ......................................................................................................... iii List of Figures ..................................................................................................................vi List of Appendices ...........................................................................................................ix List of Abbreviations ........................................................................................................ x Abstract .......................................................................................................................... xii Chapter 1 Background and Introduction ......................................................................... 1 Chapter 2 Metabolism of Bupropion by Carbonyl Reductases in Liver and Intestine ... 22 Chapter 3 Method Development, Validation, and Sample Analysis of Bupropion in Human Plasma. ............................................................................................................. 60 Chapter 4 Investigate Different Release Mechanisms that May Alter Absorption, Metabolism, and Pharmacogenomics of Bupropion. ..................................................... 81 Chapter 5 Conclusions ............................................................................................... 108 Appendices .............................................................................................................. 113 v List of Figures Figure 1-1. Subcellular Fractions. ............................................................................... 20 Figure 1-2. Generics Failed BE Standards. ................................................................ 21 Figure 2-1. Bupropion and Metabolism. ....................................................................... 48 Figure 2-2. Method Development for Bupropion and Metabolites.. .............................. 49 Figure 2-3. Hydroxybupropion Metabolite Formation in Liver Subcellular Fractions. ... 50 Figure 2-4. Threohydrobupropion Metabolite Formation in Liver Subcellular Fractions. ...................................................................................................................................... 51 Figure 2-5. Erythrohydrobupropion Metabolite Formation in Liver Subcellular Fractions.. ...................................................................................................................................... 52 Figure 2-6. Threohydrobupropion Metabolite Formation in Intestinal Subcellular Fractions.. .................................................................................................................. 53 Figure 2-7. Threohydrobupropion Metabolite Formation in Intestinal Subcellular Fractions.. ..................................................................................................................... 54 Figure 2-8. Enzyme Expression in Human Subcellular Fractions. ............................... 55 Supplemental Figure 2-1.Hepatocytes Kinetics. .......................................................... 58 Figure 3-1. MRM Chromatograms of Blank Plasma Samples for Selectivity.. .............. 71 Figure 3-2. MRM Chromatograms of Blank Samples with IS for Selectivity.. ............... 72 Figure 3-3. Specificity for Bupropion and Metabolites. .................................................. 73 Figure 3-4. Short term stability. .................................................................................. 79 Figure 3-5. Carryover. ............................................................................................... 80 Figure 4-1. Time vs Concentration Plots. .................................................................... 98 Figure 4-2. Relative Bioavailability. .............................................................................. 99 Figure 4-3. Analysis of Metabolites .. ......................................................................... 100 Figure 4-4. Pharmacogenomics of CYP2B6. ........................................................... 101 Figure 4-5. Weibull Absorption Rate........................................................................... 102 Figure 4-6. Cumulative Percent Absorbed.. ................................................................ 103 Appendix Figure 1-1. HSP90 Complex. 130 Appendix Figure 2-1. SRL-PFAC confirm that both Hsp70-PP5 and Hsp90-PP5 interact. ....................................................................................................................... 155 Appendix Figure 2-2. Fluorescence polarization confirms that Hsp90-PP5 has higher affinity than Hsp70-PP5.. ............................................................................................. 156 Appendix Figure 2-3. Competition studies confirm binding data.. .............................. 157 Appendix Figure 2-4. Hsp70-PP5 and Hsp90 interact with different stoichemetries.. 158 Appendix Figure 2-5. C-terminal residues of Hsc70 bind PP5.. ................................. 159 Appendix Figure 2-6. Hsp70 preferentially stimulates PP5’s phosphatase activity.. .. 160 vi Appendix Figure 3-1. Fluorescence Polarization Assay.. ........................................... 177 Appendix Figure 3-2. Primary Screen of TPR containing proteins-Hsp90 peptide. .... 178 Appendix Figure 3-3. Dose Response Curves from Hit Compounds. ........................ 179 Appendix Figure 3-4. Hits from DRC.. ......................................................................... 180 Appendix Figure 3-5. Suramin inhibits TPR containing proteins-Hsp90. .................. 181 Appendix Figure 3-6. Sumarin and Analogs for inhibiting Hsp90-TPR containing proteins.. ..................................................................................................................... 182 vii List of Tables Table 2-1. Summary of Subcellular Kinetics.. 56 Table 2-2. Estimated Intrinsic Clearance.. .................................................................... 57 Supplemental Table ‎2-1. Hepatocytes Kinetics Summary...................................... ...... 59 Table 3-1. MRM Parameters. .................................................................................... 70 Table 3-2. Standard Curves for Bupropion and Metabolites.. ....................................... 74 Table 3-3. Matrix Effect Analysis. .............................................................................. 75 Table 3-4. Accuracy. ................................................................................................. 76 Table 3-5. Precision. .................................................................................................. 77 Table 3-6. Recovery. ................................................................................................. 78 Table 4-1. Area Under the Curve.. ............................................................................. 104 Table 4-2. Percent of Relative Bioavailability.
Recommended publications
  • Concomitant Drugs Associated with Increased Mortality for MDMA Users Reported in a Drug Safety Surveillance Database Isaac V
    www.nature.com/scientificreports OPEN Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database Isaac V. Cohen1, Tigran Makunts2,3, Ruben Abagyan2* & Kelan Thomas4 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). If MDMA is FDA-approved it will be important to understand what medications may pose a risk of drug– drug interactions. The goal of this study was to evaluate the risks due to MDMA ingestion alone or in combination with other common medications and drugs of abuse using the FDA drug safety surveillance data. To date, nearly one thousand reports of MDMA use have been reported to the FDA. The majority of these reports include covariates such as co-ingested substances and demographic parameters. Univariate and multivariate logistic regression was employed to uncover the contributing factors to the reported risk of death among MDMA users. Several drug classes (MDMA metabolites or analogs, anesthetics, muscle relaxants, amphetamines and stimulants, benzodiazepines, ethanol, opioids), four antidepressants (bupropion, sertraline, venlafaxine and citalopram) and olanzapine demonstrated increased odds ratios for the reported risk of death. Future drug–drug interaction clinical trials should evaluate if any of the other drug–drug interactions described in our results actually pose a risk of morbidity or mortality in controlled medical settings. 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Adminis- tration (FDA) for the treatment of posttraumatic stress disorder (PTSD). During the past two decades, “ecstasy” was illegally distributed and is purported to contain MDMA, but because the market is unregulated this “ecstasy” may actually contain adulterants or no MDMA at all1.
    [Show full text]
  • Canadian Stroke Best Practice Recommendations
    CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS MOOD, COGNITION AND FATIGUE FOLLOWING STROKE Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression Update 2019 Lanctôt KL, Swartz RH (Writing Group Chairs) on Behalf of the Canadian Stroke Best Practice Recommendations Mood, Cognition and Fatigue following Stroke Writing Group and the Canadian Stroke Best Practice and Quality Advisory Committee, in collaboration with the Canadian Stroke Consortium © 2019 Heart & Stroke Heart and Stroke Foundation Mood, Cognition and Fatigue following Stroke Canadian Stroke Best Practice Recommendations Table 1C Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on selected classes of medications available for use in Canada and more commonly recommended for post-stroke depression. This table should be used as a reference guide by health care professionals when selecting an appropriate agent for individual patients. Patient compliance, patient preference and/or past experience, side effects, and drug interactions should all be taken into consideration during decision-making, in addition to other information provided in this table and available elsewhere regarding these medications. Selective Serotonin Reuptake Inhibitors (SSRI) Serotonin–norepinephrine reuptake Other inhibitors (SNRI) Medication *citalopram – Celexa *duloxetine – Cymbalta methylphenidate – Ritalin (amphetamine)
    [Show full text]
  • Methylphenidate Hydrochloride
    Application for Inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE December 7, 2018 Submitted by: Patricia Moscibrodzki, M.P.H., and Craig L. Katz, M.D. The Icahn School of Medicine at Mount Sinai Graduate Program in Public Health New York NY, United States Contact: [email protected] TABLE OF CONTENTS Page 3 Summary Statement Page 4 Focal Point Person in WHO Page 5 Name of Organizations Consulted Page 6 International Nonproprietary Name Page 7 Formulations Proposed for Inclusion Page 8 International Availability Page 10 Listing Requested Page 11 Public Health Relevance Page 13 Treatment Details Page 19 Comparative Effectiveness Page 29 Comparative Safety Page 41 Comparative Cost and Cost-Effectiveness Page 45 Regulatory Status Page 48 Pharmacoepial Standards Page 49 Text for the WHO Model Formulary Page 52 References Page 61 Appendix – Letters of Support 2 1. Summary Statement of the Proposal for Inclusion of Methylphenidate Methylphenidate (MPH), a central nervous system (CNS) stimulant, of the phenethylamine class, is proposed for inclusion in the WHO Model List of Essential Medications (EML) & the Model List of Essential Medications for Children (EMLc) for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) under ICD-11, 6C9Z mental, behavioral or neurodevelopmental disorder, disruptive behavior or dissocial disorders. To date, the list of essential medications does not include stimulants, which play a critical role in the treatment of psychotic disorders. Methylphenidate is proposed for inclusion on the complimentary list for both children and adults. This application provides a systematic review of the use, efficacy, safety, availability, and cost-effectiveness of methylphenidate compared with other stimulant (first-line) and non-stimulant (second-line) medications.
    [Show full text]
  • Systems and Chemical Biology Approaches to Study Cell Function and Response to Toxins
    Dissertation submitted to the Combined Faculties for the Natural Sciences and for Mathematics of the Ruperto-Carola University of Heidelberg, Germany for the degree of Doctor of Natural Sciences Presented by MSc. Yingying Jiang born in Shandong, China Oral-examination: Systems and chemical biology approaches to study cell function and response to toxins Referees: Prof. Dr. Rob Russell Prof. Dr. Stefan Wölfl CONTRIBUTIONS The chapter III of this thesis was submitted for publishing under the title “Drug mechanism predominates over toxicity mechanisms in drug induced gene expression” by Yingying Jiang, Tobias C. Fuchs, Kristina Erdeljan, Bojana Lazerevic, Philip Hewitt, Gordana Apic & Robert B. Russell. For chapter III, text phrases, selected tables, figures are based on this submitted manuscript that has been originally written by myself. i ABSTRACT Toxicity is one of the main causes of failure during drug discovery, and of withdrawal once drugs reached the market. Prediction of potential toxicities in the early stage of drug development has thus become of great interest to reduce such costly failures. Since toxicity results from chemical perturbation of biological systems, we combined biological and chemical strategies to help understand and ultimately predict drug toxicities. First, we proposed a systematic strategy to predict and understand the mechanistic interpretation of drug toxicities based on chemical fragments. Fragments frequently found in chemicals with certain toxicities were defined as structural alerts for use in prediction. Some of the predictions were supported with mechanistic interpretation by integrating fragment- chemical, chemical-protein, protein-protein interactions and gene expression data. Next, we systematically deciphered the mechanisms of drug actions and toxicities by analyzing the associations of drugs’ chemical features, biological features and their gene expression profiles from the TG-GATEs database.
    [Show full text]
  • Preferred Drug List Illinois Medicaid 10/1/2019: Revised 11/06/2019 for Drugs Not Found on This List, Go to the Drug Search Engine At
    Preferred Drug List Illinois Medicaid 10/1/2019: Revised 11/06/2019 For drugs not found on this list, go to the drug search engine at: www.ilpriorauth.com *Exceptions as noted above* ▪ADHD Agents: Prior authorization required for participants under 6 years of age and participants 19 years of age and older ▪Spiriva AER 1.25mcg: Prior authorization NOT required for participants ages 6-17 years ▪Budesonide: Prior authorization NOT required for participants age 7 years and under ▪Anticonvulsants: Prior authorization NOT required for non-preferred epilepsy agents for those participants with a diagnosis of epilepsy or seizure disorder in Department records ▪Antipsychotics: Prior authorization required for participants under 8 years of age and long- term care residents 1 of 27 Preferred Drug List Illinois Medicaid 10/1/2019: Revised 11/06/2019 For drugs not found on this list, go to the drug search engine at: www.ilpriorauth.com Category Preferred Preferred, Requires PA Non-Preferred ADHD Agent - Amphetamine Mixtures* AMPHETAMINE/DEXTROAMPHETAMINE ADDERALL ADDERALL XR MYDAYIS ADHD Agent - Amphetamines* VYVANSE ADZENYS ER ADZENYS XR-ODT AMPHETAMINE SULFATE DESOXYN DEXEDRINE DEXTROAMPHETAMINE SULFATE DEXTROAMPHETAMINE SULFATE ER DYANAVEL XR EVEKEO EVEKEO ODT METHAMPHETAMINE HCL PROCENTRA ZENZEDI ADHD Agent - Selective Alpha Adrenergic Agonists CLONIDINE HCL ER INTUNIV CLONIDINE HYDROCHLORIDE ER GUANFACINE ER ADHD Agent - Selective Norepinephrine Reuptake Inhibitor* ATOMOXETINE ATOMOXETINE HYDROCHLORIDE STRATTERA 2 of 27 Preferred Drug List Illinois
    [Show full text]
  • 624.Full.Pdf
    1521-009X/44/5/624–633$25.00 http://dx.doi.org/10.1124/dmd.115.068932 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:624–633, May 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations Thomas I.F.H. Cremers, Gunnar Flik, Joost H.A. Folgering, Hans Rollema, and Robert E. Stratford, Jr. Brains On-Line BV, Groningen, The Netherlands (T.I.F.H.C., G.F. J.H.A.F.); Rollema Biomedical Consulting, Mystic, Connecticut (H.R.); and Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, Pittsburgh, Pennsylvania (R.E.S.) Received December 11, 2015; accepted February 24, 2016 Downloaded from ABSTRACT Administration of bupropion [(6)-2-(tert-butylamino)-1-(3-chlorophenyl) concentration ratio at early time points was observed with propan-1-one] and its preformed active metabolite, hydroxybupropion bupropion; this was modeled as a time-dependent uptake clear- [(6)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methyl-2-propanyl)amino]- ance of the drug across the blood–brain barrier. Translation of the 1-propanone], to rats with measurement of unbound concentrations model was used to predict bupropion and hydroxybupropion dmd.aspetjournals.org by quantitative microdialysis sampling of plasma and brain extra- exposure in human brain extracellular fluid after twice-daily cellular fluid was used to develop a compartmental pharmacoki- administration of 150 mg bupropion. Predicted concentrations netics model to describe the blood–brain barrier transport of both indicate that preferential inhibition of the dopamine and norepi- substances.
    [Show full text]
  • Levomilnacipran (Fetzima®) Indication
    Levomilnacipran (Fetzima®) Indication: Indicated for the treatment of major depressive disorder (MDD), FDA approved July 2013. Mechanism of action Levomilnacipran, the more active enantiomer of racemic milnacipran, is a selective SNRI with greater potency for inhibition of norepinephrine relative to serotonin reuptake Compared with duloxetine or venlafaxine, levomilnacipran has over 10-fold higher selectivity for norepinephrine relative to serotonin reuptake inhibition The exact mechanism of the antidepressant action of levomilnacipran is unknown Dosage and administration Initial: 20 mg once daily for 2 days and then increased to 40 mg once daily. The dosage can be increased by increments of 40 mg at intervals of two or more days Maintenance: 40-120 mg once daily with or without food. Fetzima should be swallowed whole (capsule should not be opened or crushed) Levomilnacipran and its metabolites are eliminated primarily by renal excretion o Renal impairment Dosing: Clcr 30-59 mL/minute: 80 mg once daily Clcr 15-29 mL/minute: 40 mg once daily End-stage renal disease (ESRD): Not recommended Discontinuing treatment: Gradually taper dose, if intolerable withdrawal symptoms occur, consider resuming the previous dose and/or decrease dose at a more gradual rate How supplied: Capsule ER 24 Hour Fetzima Titration: 20 & 40 mg (28 ea) Fetzima: 20 mg, 40 mg, 80 mg, 120 mg Warnings and Precautions Elevated Blood Pressure and Heart Rate: measure heart rate and blood pressure prior to initiating treatment and periodically throughout treatment Narrow-angle glaucoma: may cause mydriasis. Use caution in patients with controlled narrow- angle glaucoma Urinary hesitancy or retention: advise patient to report symptoms of urinary difficulty Discontinuation Syndrome Seizure disorders: Use caution with a previous seizure disorder (not systematically evaluated) Risk of Serotonin syndrome when taken alone or co-administered with other serotonergic agents (including triptans, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone, and St.
    [Show full text]
  • Levomilnacipran for the Treatment of Major Depressive Disorder
    Out of the Pipeline Levomilnacipran for the treatment of major depressive disorder Matthew Macaluso, DO, Hala Kazanchi, MD, and Vikram Malhotra, MD An SNRI with n July 2013, the FDA approved levomil- Table 1 once-daily dosing, nacipran for the treatment of major de- Levomilnacipran: Fast facts levomilnacipran pressive disorder (MDD) in adults.1 It is I Brand name: Fetzima decreased core available in a once-daily, extended-release formulation (Table 1).1 The drug is the fifth Class: Serotonin-norepinephrine reuptake symptoms of inhibitor serotonin-norepinephrine reuptake inhibi- MDD and was well Indication: Treatment of major depressive tor (SNRI) to be sold in the United States disorder in adults tolerated in clinical and the fourth to receive FDA approval for FDA approval date: July 26, 2013 trials treating MDD. Availability date: Fourth quarter of 2013 Levomilnacipran is believed to be the Manufacturer: Forest Pharmaceuticals more active enantiomer of milnacipran, Dosage forms: Extended–release capsules in which has been available in Europe for 20 mg, 40 mg, 80 mg, and 120 mg strengths years and was approved by the FDA in Recommended dosage: 40 mg to 120 mg 2009 for treating fibromyalgia. Efficacy of capsule once daily with or without food levomilnacipran for treating patients with Source: Reference 1 MDD was established in three 8-week ran- domized controlled trials (RCTs).1 cial and occupational functioning in addi- Clinical implications tion to improvement in the core symptoms Levomilnacipran is indicated for treating of depression.5
    [Show full text]
  • Preclinical Evaluation of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma by Andrea Shergalis
    Preclinical Evaluation of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma By Andrea Shergalis A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Medicinal Chemistry) in the University of Michigan 2020 Doctoral Committee: Professor Nouri Neamati, Chair Professor George A. Garcia Professor Peter J. H. Scott Professor Shaomeng Wang Andrea G. Shergalis [email protected] ORCID 0000-0002-1155-1583 © Andrea Shergalis 2020 All Rights Reserved ACKNOWLEDGEMENTS So many people have been involved in bringing this project to life and making this dissertation possible. First, I want to thank my advisor, Prof. Nouri Neamati, for his guidance, encouragement, and patience. Prof. Neamati instilled an enthusiasm in me for science and drug discovery, while allowing me the space to independently explore complex biochemical problems, and I am grateful for his kind and patient mentorship. I also thank my committee members, Profs. George Garcia, Peter Scott, and Shaomeng Wang, for their patience, guidance, and support throughout my graduate career. I am thankful to them for taking time to meet with me and have thoughtful conversations about medicinal chemistry and science in general. From the Neamati lab, I would like to thank so many. First and foremost, I have to thank Shuzo Tamara for being an incredible, kind, and patient teacher and mentor. Shuzo is one of the hardest workers I know. In addition to a strong work ethic, he taught me pretty much everything I know and laid the foundation for the article published as Chapter 3 of this dissertation. The work published in this dissertation really began with the initial identification of PDI as a target by Shili Xu, and I am grateful for his advice and guidance (from afar!).
    [Show full text]
  • Monoamine Reuptake Inhibitors in Parkinson's Disease
    Hindawi Publishing Corporation Parkinson’s Disease Volume 2015, Article ID 609428, 71 pages http://dx.doi.org/10.1155/2015/609428 Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review article summarises all of the available literature on use of 50 MAUIs in PD. The compounds are divided according to their relative potency for each of the monoamine transporters.
    [Show full text]
  • The Effect of Altering Brain CYP2B Activity on Nicotine Self-Administration Behaviour and Nicotine Levels in the Brain
    The Effect of Altering Brain CYP2B Activity on Nicotine Self-Administration Behaviour and Nicotine Levels in the Brain by Kristine Garcia A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Pharmacology and Toxicology University of Toronto © Copyright by Kristine Garcia 2016 The Effect of Altering Brain CYP2B Activity on Nicotine Self- Administration and Nicotine Levels in the Brain Kristine Garcia Doctor of Philosophy Pharmacology and Toxicology University of Toronto 2016 Abstract Cytochrome P450 (CYP) enzymes play an important role in drug metabolism. While CYPs are abundantly expressed in the liver, where CYP-mediated drug metabolism typically occurs, these enzymes are also expressed in other tissues such as the brain. Local brain drug metabolism can influence the response to drugs that act within the brain. The CYP subfamily 2B (CYP2B) is expressed in the brain and is responsible for metabolizing many central nervous system (CNS)- acting drugs including nicotine, the main psychoactive ingredient in cigarettes. Genetic variation in human CYP2B6 is associated with greater conversion to nicotine dependence and risk of relapse in smokers without influencing peripheral nicotine metabolism. This suggests that local brain nicotine metabolism could influence nicotine levels that in turn mediate nicotine reinforcement and resulting behaviours. The role of brain CYP2B activity in nicotine reinforcement was investigated by injecting a pharmacological CYP2B inhibitor into the brain of rats that then underwent nicotine self-administration (NSA), which models smoking behaviour. Inhibitor-treatment increased NSA acquisition, motivation to obtain nicotine and the number of sessions required to extinguish behaviour, suggesting that inhibiting brain CYP2B activity can augment nicotine-reinforced behaviour.
    [Show full text]
  • Antidepressants, Other Review 04/14/2009
    Antidepressants, Other Review 04/14/2009 Copyright © 2004 - 2009 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be
    [Show full text]